ArticleChemistry (Weinheim an der Bergstrasse, Germany)2026
C-Terminal Nucleobase Modification Amplifies Peptide-Mediated Liposome Fusion.
Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- C-Terminal Nucleobase Modification Amplifies Peptide-Mediated Liposome Fusion.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The discovery of novel fusion peptides with enhanced properties is crucial for advancing our understanding of membrane fusion processes and developing more efficient tools for biotechnology and medicine. Currently, fusion peptides are mostly identified as portions of viral fusion proteins, and this limits their versatility. This study presents a significant step forward by demonstrating that end-capping a cationic helical peptide with a nucleobase substantially enhances its ability to induce liposome fusion. We show that a helical trichogin analog, Oct-K2569Tric-Lol, containing four lysine residues, induces reversible aggregation of negatively charged liposomes in a concentration-dependent manner. Remarkably, we found that the addition of a single thymine nucleobase at the C-terminus of this peptide (Oct-K2569Tric-T) transforms its activity from reversible aggregation to irreversible membrane fusion. Furthermore, we observed that the presence of complementary nucleobases at both peptide termini promotes membrane fusion even at peptide-to-lipid ratios that do not cause membrane leakage. Our findings provide a new strategy for designing more potent fusion peptides, opening possibilities for improved applications in drug delivery, cell biology research, and nanotechnology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.